Diagnosis, Dual (Psychiatry) Clinical Trial
Official title:
Validation of a Dual Integrated Attention Program (DAIP) in People With Severe Dual Diagnosis Admitted to a Psychiatric Hospitalization Unit
Aim: validate a Dual Integrated Attention Program (D-AIP) for mental health nursing in people
with Severe Dual Diagnosis admitted to a psychiatric hospitalization unit
Design: Randomized Controlled Trial. Population: Inpatients with dual diagnosis.
The main objective of the project is to validate a Dual Integrated Attention Program (D-AIP)
for mental health nursing in people with Severe Dual Diagnosis admitted to a psychiatric
hospitalization unit, assessing change motivation, insight, medication adherence, drug
consumption abstinence or reduction, therapeutic alliance, hopelessness and anxiety, which
this context generates. For this purpose, a randomized, prospective, one-year-longitudinal
clinical trial will be conducted. This study will be applied on patients with diagnosis of
schizophrenia, schizoaffective disorder and bipolar disorder types I and II who, after
accepting to participate in the study and signing the informed consent, answer the PRISM
questionnaire of admission in the hospitalization unit and fulfill the dual pathology
criteria. After, they will be randomized in control group and intervention group (only the
later will complete the D-AIP).
The D-AIP will consist on 6 individualized sessions with the psychiatric inpatients, and
during follow-up up to one year after discharge in which 4 individual sessions and 3
telephone contacts will be made. In both groups, a different person from the one who performs
the intervention and without knowledge of the group belonging will assess them with
questionnaires in 9 moments during the whole follow-up year (Socrates 8D, Scale of
Unawareness of Mental Disorder "SUMD", Morisky Medication Adherence Scale "MMAS-8", Working
Alliance Inventory "WAI", Hamilton Anxiety Rating Scale "HARS" y Hopelessness Scale "HS") and
will collect a urine sample in each evaluation. The sample size will be 86 subjects, for
α=0.05 and power=0.80.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00583440 -
12-step Facilitation for the Dually Diagnosed
|
Phase 1/Phase 2 | |
| Completed |
NCT00237822 -
Increasing Treatment Adherence in Co-Occurring Psychiatric and Drug Use Disorders
|
Phase 2 | |
| Completed |
NCT05103865 -
Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions
|
N/A | |
| Not yet recruiting |
NCT05115266 -
Efficacy of Animal-assisted Therapy in Patients With Borderline Personality Disorder and Addictions.
|
N/A | |
| Active, not recruiting |
NCT01135420 -
Dual Diagnosis Inpatients: Telephone Monitoring RCT to Improve Outcomes
|
Phase 2 |